Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000824778 | SCV000065431 | likely pathogenic | Rare genetic deafness | 2008-03-01 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000725789 | SCV000339396 | pathogenic | not provided | 2016-02-17 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000041735 | SCV000487486 | pathogenic | Usher syndrome type 2A | 2016-08-18 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000410671 | SCV000487487 | pathogenic | Retinitis pigmentosa 39 | 2016-08-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000725789 | SCV000955119 | pathogenic | not provided | 2023-04-25 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 48412). This premature translational stop signal has been observed in individuals with USH2A-related conditions (PMID: 22135276, 25558175). This variant is present in population databases (rs111033385, gnomAD 0.002%). This sequence change creates a premature translational stop signal (p.Ser4377*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). |
Genome- |
RCV000410671 | SCV004181905 | likely pathogenic | Retinitis pigmentosa 39 | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000041735 | SCV004181906 | likely pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000410671 | SCV004206385 | pathogenic | Retinitis pigmentosa 39 | 2022-10-04 | criteria provided, single submitter | clinical testing |